N
Google TrendLIONESS SEASON 3 (5000+) — Thank Zoe Saldaña for ‘Lioness’ Season 3’s Perfect Cliff-Hanger
The 24/7 Global Portal

World News, Markets & Google Trends

Aggregated real-time headlines, trending Google search queries, and verified dispatches in one single page.

Google Trends:lioness season 35000+luis díaz200+lamine yamal5000+thélyson orélien500+abdulrahman alfozan500+pope francis500+delaware vs middle tennessee prediction1000+pablo torre500+
Category:All HeadlinesWorld & GeopoliticsMarkets & EconomyTech & AIPoliticsSearch results for: "Tarlatamab Demonstrates S" (30 stories)

Top Headline Story

Tarlatamab Demonstrates Superior Intracranial and Systemic Efficacy in Relapsed Extensive-Stage Small Cell Lung Cancer: Results from the Phase 3 DeLLphi-304 Trial and Real-World Analyses
Lead StoryOnco'Zineworld
Jun 1

Tarlatamab Demonstrates Superior Intracranial and Systemic Efficacy in Relapsed Extensive-Stage Small Cell Lung Cancer: Results from the Phase 3 DeLLphi-304 Trial and Real-World Analyses

<a href="https://news.google.com/rss/articles/CBMitgJBVV95cUxOa1ZuU1JqOVZ4NDJWR0FnSjJLbWU5QW9HTXZCZzhaaEw5S08wMWxBUXpYT3EyVjljU1NEdS1xV3o4bUF1RXNQNVcyZTJjVzU5RjRQb0NKNDdGMXhBQ1I0UEhqRWNMMjh0N2dqbEFYcVBWS2V0eUs2VUQwUFE2UnVqRkZqX2wwRzFYRjhENU5MNmtrMUUwS25sVXhIZWRBa0VUZWZsQjJrYXhzbHFzQzlwLVhDMjdyVExuS014c1Y1RThsM0RBdlhGc1RqZy10R19yNENRVFQySmZiVE9GM3V2dkh6bnN2S3FGU1VYRWxJMmh4VmtJM1g3cFhsSHR5dEVMcnNLNE1vM1QwOTRBWGxGbDg0Y2liLXNDUkdmcWFwUGVPanN6aTE4eVlrVjZBalgyTTlMVkZn?oc=5" target="_blank">Tarlatamab Demonstrates Superior Intracranial and Systemic Efficacy in Relapsed Extensive-Stage Small Cell Lung Cancer: Results from the Phase 3 DeLLphi-304 Trial and Real-World Analyses</a>  <font color="#6f6f6f">Onco'Zine</font>

Read Full StoryRelated Trends

Google Trends & Trending Search Intelligence

Real-time search volume
5000+14m ago

lioness season 3

Thank Zoe Saldaña for ‘Lioness’ Season 3’s Perfect Cliff-Hanger

Filter stories
200+24m ago

luis díaz

Max Eberl knows Luis Díaz will start scoring again for Bayern Munich

Filter stories
5000+34m ago

lamine yamal

"You want to play for Morocco?": Getafe defender provokes Yamal with shocking words

Filter stories
500+34m ago

thélyson orélien

Acclaimed Author Denies Using A.I. but Admits Plagiarism

Filter stories

Search Results for "Tarlatamab Demonstrates S"

Updated every 3 minutes via FreeNewsApi, GNews, Currents API & Google News

29 stories displayed
IMFINZI® (durvalumab) plus tarlatamab demonstrated a statistically significant and highly clinically meaningful improvement in overall survival and progression-free survival in 1st-line extensive-stage small cell lung cancer
Yahoo Financeworld

IMFINZI® (durvalumab) plus tarlatamab demonstrated a statistically significant and highly clinically meaningful improvement in overall survival and progression-free survival in 1st-line extensive-stage small cell lung cancer

<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxOTjl2NkRkY2FlX1dMNXdQeWZUcHVzSF9YLTBKcTIyUkJTcVg0dTJENHJCMnZVM1pUTlczOXVuN0JCejBhYkNwZy1qTTNzRGg0dmpFd1lJcGtvVm9HMmRJbDJ3WG9MR0o0Q09BaHdFX2R2TkJKb2VZdVZQeDZTWWZsTnpyaUxNM2xyaTB5cFpibXlMcGFQNmthVGlBT1NONTBKWjJIWHBGUjVETG5X?oc=5" target="_blank">IMFINZI® (durvalumab) plus tarlatamab demonstrated a statistically significant and highly clinically meaningful improvement in overall survival and progression-free survival in 1st-line extensive-stage small cell lung cancer</a>  <font color="#6f6f6f">Yahoo Finance</font>

Read Full StoryMore like this
Laura Alder: Tarlatamab Demonstrates Strong Responses in DLL3-High Pulmonary Carcinoid
Oncodailygeneral

Laura Alder: Tarlatamab Demonstrates Strong Responses in DLL3-High Pulmonary Carcinoid

<a href="https://news.google.com/rss/articles/CBMiXEFVX3lxTE5OM2JmbXhGOXlhVGY5Sms5aF9HU1RPdGZqaXNfdFdKcWdRNGN1andmOEJwcHdoRWxhNmpGQ2I4dG9veDVYbzVKV0tkdlNNeFlwbERCYmNza0pGdDlO?oc=5" target="_blank">Laura Alder: Tarlatamab Demonstrates Strong Responses in DLL3-High Pulmonary Carcinoid</a>  <font color="#6f6f6f">Oncodaily</font>

Read Full StoryMore like this
Immunotherapy Combo Fails to Improve Survival in Limited-Stage Small Cell Lung Cancer
Oncology News Centraltech

Immunotherapy Combo Fails to Improve Survival in Limited-Stage Small Cell Lung Cancer

<a href="https://news.google.com/rss/articles/CBMixAFBVV95cUxOVDFaaVhQVFlUdXdGZ0lCc18zbjlIOVFzdE9YcXcwNFJUdlM5c2NwcEdra3RIcHhINEJHUWgyblk1Y1Z4X0dUOFU4WG1RNmlQQzM3Y3doQjFici1lZENxM29VYlBoZWVWdUVBZGZWSWFXUTl4LW0yTFQzRmk3Z1lzM1kwM2tPTHhvX0tBSEZlYllyQWE1cHBYZ1RMWmNNb3AxUzBSR2RLdWdSSGNxSlZYb3J5d3NFX01PRDNHXzNCQV92ZnYt?oc=5" target="_blank">Immunotherapy Combo Fails to Improve Survival in Limited-Stage Small Cell Lung Cancer</a>  <font color="#6f6f6f">Oncology News Central</font>

Read Full StoryMore like this
Tarlatamab Plus Chemo/IO Regimens Are Safe, Elicit Responses in ES-SCLC
CancerNetworkgeneral

Tarlatamab Plus Chemo/IO Regimens Are Safe, Elicit Responses in ES-SCLC

<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxOVXpnU0pXRy1vRFZxQ3d0b2QtTGJfRGdDcGRsY2M5bm5aQmE2UHhubE5ONGd3UVVWbVdiYXVjWjltdHpRVWZSMlZDem1fZF9Id1JmaThyazVpTVpQVWF5MXFkYnhIeE9UYjNBdHRremN3TC1JcnkyZ3BXaks2bWtHYXRCMjBOYk02VGc0WHpWa0EwazJqWXl6LWhkUklPLW1SX2RWQ2ZkTHQ?oc=5" target="_blank">Tarlatamab Plus Chemo/IO Regimens Are Safe, Elicit Responses in ES-SCLC</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryMore like this
Second-Line Tarlatamab Shows Improved Survival Over Chemotherapy in Previously Treated SCLC
ASCO Daily Newsgeneral

Second-Line Tarlatamab Shows Improved Survival Over Chemotherapy in Previously Treated SCLC

<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxPR21mVmU0Si1PaXRJdjNNOG5wNlFyRDNXeGowcGlWblBPRXlUZGlWbm5FWEhUWjduc2xGNTZwbVRod3BkdWdlMUlUOXJXemp4dGVOWEliQUJWc1pNZmtkTVl5VUF6TVQ3TllZUk9PbFZtMUlKM2hfMkhELTV2cFVZZU84Yi1rY2pQa0RVZEZTSzZPQ3hhVVhBbENtS0hMSl9EYW5EejVPY1BnQUJUZklta25hYWdiMGJZ?oc=5" target="_blank">Second-Line Tarlatamab Shows Improved Survival Over Chemotherapy in Previously Treated SCLC</a>  <font color="#6f6f6f">ASCO Daily News</font>

Read Full StoryMore like this
Tarlatamab for Previously Treated Small Cell Lung Cancer
National Cancer Institute (.gov)world

Tarlatamab for Previously Treated Small Cell Lung Cancer

<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxQSWlmM2xQUjN1MzVVR205Znc1WU9aUE5Qc2YwNWxBYldaX1NwVTlyeTVyT1RIVDZXbWpuZE8zVGNmb25wVUR4WkxkZFB6ZFZkclQ3NF85ZU94RXBHQkk2WWQ2ZVJkaE5kcE40SGNTRk9FTERtWjc3X3pVcVNMZjJwRElGS3JDT2lDOXQ2YVFXaUlHSEYzSWNGMk5taw?oc=5" target="_blank">Tarlatamab for Previously Treated Small Cell Lung Cancer</a>  <font color="#6f6f6f">National Cancer Institute (.gov)</font>

Read Full StoryMore like this
Tarlatamab Demonstrates Early Safety and Activity in DLL3+ Neuroendocrine Prostate Cancer
OncLivegeneral

Tarlatamab Demonstrates Early Safety and Activity in DLL3+ Neuroendocrine Prostate Cancer

<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxQVmpOdFh2czJtLUVVaEU5WUZObFJJeTBLZi03V3NleFFvMjFmR1owZ20xV0lNRlFBQXhIZ1VEZ1RxUThUbTBYeTgzUDh4bldtMWxlU3YxcEE0UHlqMUh5VER3N2loUDZTQXBZaUZyZkpDQTBBRmNnQ1lZV2tLMFFTRjY5Qk1nYUdveDF6aWtaU0VuYzlXd1ZTbU4zTUZYRmVFSTIySTFSRHU5VW1scUpxNG1ZRk10VXpQ?oc=5" target="_blank">Tarlatamab Demonstrates Early Safety and Activity in DLL3+ Neuroendocrine Prostate Cancer</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
IMDELLTRA® IN COMBINATION WITH IMFINZI® DEMONSTRATED LANDMARK IMPROVEMENT IN OVERALL SURVIVAL IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER
PR Newswireworld

IMDELLTRA® IN COMBINATION WITH IMFINZI® DEMONSTRATED LANDMARK IMPROVEMENT IN OVERALL SURVIVAL IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER

<a href="https://news.google.com/rss/articles/CBMipwJBVV95cUxPMkptdER6azUydGRTSFpieXZhLWxySm53U0tuZ3ZhOU9taU8wWnk4YVJrRGwwLVpXZXFxSFlRRWRNRDVHckNXR0ctTTlQOXZKRjdDOEdodTdPeG1ENzk2NDBGRkJsNnUweUdlekJIV19iamxTUG5mVU5Sa0JpT2VjRGozU1RUVVRNNndtcnNHWVd6SWFRQmhObDBKX2dNZlVjd3NTX2w0NUVFVE1XbXdjdUMtbjNiNG9wLXlvRXhaVUtTRnFJZXJQSzduTF9jZm5EaXI4Y3NfY3E1bHpFVlFuUzZiNWNmUTB2bUp5TjRpVlJPRWpQdXBiV3hLa2FfQnMzQzZKUEFQZktRbmgzT0pXbTVDRlF5dUF4V2JIZ2FFeFV5R295VWFr?oc=5" target="_blank">IMDELLTRA® IN COMBINATION WITH IMFINZI® DEMONSTRATED LANDMARK IMPROVEMENT IN OVERALL SURVIVAL IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER</a>  <font color="#6f6f6f">PR Newswire</font>

Read Full StoryMore like this
Tarlatamab Combination Regimen Demonstrates Potential as Maintenance Therapy in ES-SCLC
Pharmacy Timestech

Tarlatamab Combination Regimen Demonstrates Potential as Maintenance Therapy in ES-SCLC

<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxQdndYQmFnUDNKOHJudTJ5OE1nQXlrX0ZoRmFEMlJMdXlXM3BLQ2JSQjhjY0xwN3JzR3VOOUhWOGxBSWhVei1QeHVVbkdIUWh1eVVCQjlqR3BObkVyZ2w5SGtEVzJRS3U5aU9jUjR5Qld0cDZ0cGFVbTJvY0x5YjdMX3EybjhGVFlGWk1vc2owbjdiYkYxUll0MkFmZEEtd0ZERzZGNjlQcXcxanNkaTVoYjhxczllVnBKTjBTbWFqMA?oc=5" target="_blank">Tarlatamab Combination Regimen Demonstrates Potential as Maintenance Therapy in ES-SCLC</a>  <font color="#6f6f6f">Pharmacy Times</font>

Read Full StoryMore like this
Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer
NEJMworld

Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer

<a href="https://news.google.com/rss/articles/CBMiYEFVX3lxTFA3NGR1emRhdEZ3a011czZfaGpkRmJuU0o4QThwcnhxbWJLZ3ZfeWczZjNrZWlrRXVsQUgwQnFsUkVPcUdNNjU4M0UwV3dFVFZ1T1pMS0xkcGpBNHpaTmVqbA?oc=5" target="_blank">Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer</a>  <font color="#6f6f6f">NEJM</font>

Read Full StoryMore like this
Phase III DeLLphi-304 Trial Finds Imdelltra Significantly Extends Survival in Relapsed Small-Cell Lung Cancer
Applied Clinical Trials Onlineworld

Phase III DeLLphi-304 Trial Finds Imdelltra Significantly Extends Survival in Relapsed Small-Cell Lung Cancer

<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxPbU5EYkhvbmlnYVJZWWxFN3RnYlBoU3JKOEZ0LWRjRW04dTFQWXdSeTUyR1lxUGltU0lfU3JDRThFd2doaWsxTzdoTkVNT3MwdEpEUE91UHhRWHlyMjUtNGpULTF3b1FCdi0ybzYzVFFaQTFVNVpzTGxHeFQxV09jcWVPd0FCX1NkQ205YkVLaFJLMGthZ2JsVHZFWURyZUpxUVVaSTdJSHZPQVE?oc=5" target="_blank">Phase III DeLLphi-304 Trial Finds Imdelltra Significantly Extends Survival in Relapsed Small-Cell Lung Cancer</a>  <font color="#6f6f6f">Applied Clinical Trials Online</font>

Read Full StoryMore like this
Tarlatamab Displays Overall Survival Benefit in Relapsed SCLC
CancerNetworkgeneral

Tarlatamab Displays Overall Survival Benefit in Relapsed SCLC

<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxPc2NaaUZwd2VnUTl3UGJ4ZjN1VmJJellvaS1TNzNKQVFfVXN2MEttbFU2WW51clI2N2RfQmFBN3NqRk96cXUtbTh1OXZMOE1odnctX1pqbUtaR2xuMWJodDlkWnJBRGdEWkJ5VWNwa1N3VWdHTHlQQk5hSGxiaVJycDk0aEIwcWdRUlgta3NLbU5vVnZFLWpOenlHd0k?oc=5" target="_blank">Tarlatamab Displays Overall Survival Benefit in Relapsed SCLC</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryMore like this
IMDELLTRA® DEMONSTRATED SUPERIOR OVERALL SURVIVAL IN SMALL CELL LUNG CANCER
PR Newswireworld

IMDELLTRA® DEMONSTRATED SUPERIOR OVERALL SURVIVAL IN SMALL CELL LUNG CANCER

<a href="https://news.google.com/rss/articles/CBMiygFBVV95cUxPQzhWUXg0ZmFxcDdwSHdXbEZHNXZTVXpoWk51eDNobWR5UmdHS2RJZnRIMFRiQU9NbWpTcDRVNnFwSU9HWUVSYkM1b2NQOWoxQlc3V2M2azE3QTNKUHZINHhEX3htanVrTFVxOGdoN2otYWc4WlV1eHgyYkRUSDBRU29MX0FoNU14UDhHZjhBU3pFbzRzdGcwOHhFZ1FrRFFZQWE4NkRyNDNhM1dMVGs0N3lhZEh1dHg4RnlRZ3FPUks0MjhscnFZNEpR?oc=5" target="_blank">IMDELLTRA® DEMONSTRATED SUPERIOR OVERALL SURVIVAL IN SMALL CELL LUNG CANCER</a>  <font color="#6f6f6f">PR Newswire</font>

Read Full StoryMore like this
Durvalumab Plus Tarlatamab Boosts Survival as First-Line ES-SCLC Maintenance
OncLivetech

Durvalumab Plus Tarlatamab Boosts Survival as First-Line ES-SCLC Maintenance

<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxQTTJjOEUzM2pEd2szLUduSGtIOVp5bmdEQ1dZNUxlMkF5RVhPSFZENUVNMFVBbjhRZ1pqelNJcEhsellEdGhvSndoZVZQVFZYRmV3ZkI0OFVRNXBYTXVtVm5CWFdhcV9RQWZnT3puNGw1MFRsMmRvMlNTQlBuVHpDYm1lUzcySEdGZEZzUkoyNndSZ2V0THZKZ0FGb3c1c0EwMVY3MmowNUk?oc=5" target="_blank">Durvalumab Plus Tarlatamab Boosts Survival as First-Line ES-SCLC Maintenance</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
Tarlatamab Shows Promising Real-World Activity in Extensive-Stage SCLC
CancerNetworkworld

Tarlatamab Shows Promising Real-World Activity in Extensive-Stage SCLC

<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxQS29HU0tUN2hrd1h0bTRIUEVXMmtWTlpOUWQ5TC1pcUsyRnNpdm01VVh6Sk0xNXdrdzBuWTkxQVN2TXAtbjNzQVhXN0RhZlVMNEs3TEx6aFJONXlmVXNKNE5JblV4amlNLU5SM2lXUGRiWlZHWjRPcl9ITzNMaWZVa0x3SVdDSWMtMEk3dkc5U1NVazY3a0R6NEIxM2prbGpma0tCUkVTY2g?oc=5" target="_blank">Tarlatamab Shows Promising Real-World Activity in Extensive-Stage SCLC</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryMore like this
Tarlatamab Plus Anti–PD-L1 Therapy as Frontline Maintenance Shows Unprecedented OS in ES-SCLC
OncLivetech

Tarlatamab Plus Anti–PD-L1 Therapy as Frontline Maintenance Shows Unprecedented OS in ES-SCLC

<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxQQm4xM0dKNjNobFZOX045bGc5QmpFSmRJZEEtQm85aGFPVTl0aFZjV2cyZE5abnVWMF8wNUZtRXNCbmhJOU93dFRzX3pQdDMwaDc1d05RZGk0RU9ZMjlraEIyb1dTS1dHbm9yTGdZNHBwTkF5TkFIR3hkSjBWMlBDejBSNFJiLWxwS2NiUC1VZEtqY3RCd1V4WDZDbXhTS2VHYXg3cHdjRG1IekdvdGM2UHRyUFhDYzE5d2JLdmtqZw?oc=5" target="_blank">Tarlatamab Plus Anti–PD-L1 Therapy as Frontline Maintenance Shows Unprecedented OS in ES-SCLC</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
Durvalumab Combo Improves Survival in First-Line Extensive-Stage SCLC
CancerNetworkgeneral

Durvalumab Combo Improves Survival in First-Line Extensive-Stage SCLC

<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxOT3FuamEwSUVXbVFvRG9hTmJOMkJkZWYyQXhkUTY4SVJ6OWw1UEJzbWpUamJSY3ZET2JQb1haWW5RMzI2ckJISlNDN0E4TTctT1FsRk9JaGRDRW5SWlhjWUxKeHo0TEVadUw3cDlfbFN0ZlFib0kwR0JHRWZ0NFI5QWhaNlh0dGhLV3JhQVEycE5aWEtvTTVCQTB2MGRWUlNqYlFzc3V3dw?oc=5" target="_blank">Durvalumab Combo Improves Survival in First-Line Extensive-Stage SCLC</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryMore like this
Tarlatamab Improves OS vs Chemotherapy in SCLC, Regardless of Prior PD-(L)1 Therapy or CFI Duration
OncLivegeneral

Tarlatamab Improves OS vs Chemotherapy in SCLC, Regardless of Prior PD-(L)1 Therapy or CFI Duration

<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxOdWFycml2elluanlSd3c5ZWNvZ1J5SU4zNlo0eHhESDZuNnl4aWZnUkJZS0Q2M0sybngtSldlcjhVbmFQLWZxbXFBV3BSZlhYQ19KRU1MMVdTNFFQUTZFYjU2Nnp2UXV4VUFjazMzMkFEMHB3VVNhTngyUWE4c1lVYy1NaFVQT3JTWDdRblFtczlhSWY4ZXJYVk9uMVNjRWlPbzBvVjJaZ0xzN2VKVS02X0ZRUFVTYzlpYnp3aHpoUkI4UDRuZ2c?oc=5" target="_blank">Tarlatamab Improves OS vs Chemotherapy in SCLC, Regardless of Prior PD-(L)1 Therapy or CFI Duration</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
Tarlatamab and DLL3 May Open New Opportunities in SCLC Management
CancerNetworkworld

Tarlatamab and DLL3 May Open New Opportunities in SCLC Management

<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxPdTdabjQ3VTdyU19RMGpUd1NTWGREY05RMnE2ZkhXSDhIZ3lWYlEtNWN1MWFjdllfRmpRWkNVME5ueEVKckR5T2ZiaVQ5YUJ1Q3IxUUJQeGNlU2pxV3JqU2xTMDMwdmd6YVktTEFsN1loQlhlN0JrNlpCS2hsMlM5UDV1MlR6andES2tUampCc05SaGpjanlIQldGT3hwWk1tR1E?oc=5" target="_blank">Tarlatamab and DLL3 May Open New Opportunities in SCLC Management</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryMore like this
Tarlatamab Monotherapy Is Safe, Active in DLL3+ Neuroendocrine Prostate Cancer
OncLivegeneral

Tarlatamab Monotherapy Is Safe, Active in DLL3+ Neuroendocrine Prostate Cancer

<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxQdEc3UG1XVGZfVzE5Y2RPWWVaWTRqcXYtSGRtSEl3N3R6R0VzREIyU0VGRkh6OUx1UUdSQ01JSmM4UmFMbjRKUFNKMUZSYkl4dUFkdXlQZ3R3enpKaTIwN0t3RzdaM2pSV1B2dTdOcm13SUgzbEVXM1RoVzZTYjZtc3lkd2JqS0kwRWhrR3F3aDhwVHgtbkpVQzhiZHYzcktSZG5kTjh2RUU?oc=5" target="_blank">Tarlatamab Monotherapy Is Safe, Active in DLL3+ Neuroendocrine Prostate Cancer</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
Continuation of Tarlatamab With Concomitant Radiotherapy for Oligoprogression in Extensive-Stage Small-Cell Lung Cancer: A Report of Two Cases
Cureusworld

Continuation of Tarlatamab With Concomitant Radiotherapy for Oligoprogression in Extensive-Stage Small-Cell Lung Cancer: A Report of Two Cases

<a href="https://news.google.com/rss/articles/CBMijAJBVV95cUxOSlFYR1ZKU0NGeXN2SUxsdkRwclczUThBRmRselFBYUFfNkpvYkoxLS0tWGFCa21vVzBBNFduR2NyR1V4QjhoMk91eVhMaGF1U2xxclBCUnlyTVg0UXh5NE1rdnk3YWpRamFKVEtTODg3cVBsOWhYMmRRQnE0d0E3MkdaS1RYV3Ric2QzZEFoczBiaW1GMGVTTGtjVTZMbEJFSmRtQ1Ixc3JTbVFJQkVVcWhuNlREeUlJVi1WbVk0RTZXX3R1NmZnOVRfWHp5WjhXeFRSQW9pNzNzNEdQNUg5VEM3a0Rrby1jSUt2LVFWWW9KX3VaZWU3NmxCcDlfVUM3UjVCWDJMbWlHdE52?oc=5" target="_blank">Continuation of Tarlatamab With Concomitant Radiotherapy for Oligoprogression in Extensive-Stage Small-Cell Lung Cancer: A Report of Two Cases</a>  <font color="#6f6f6f">Cureus</font>

Read Full StoryMore like this
DeLLphi-301 Analysis: Tarlatamab Is Active in SCLC, Regardless of Baseline Brain Metastases
DocWireNewstech

DeLLphi-301 Analysis: Tarlatamab Is Active in SCLC, Regardless of Baseline Brain Metastases

<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxPQ1hwamFOQ1pyQ2laRVdXaU1WV1BxUUZmUjNLbFA2N1FKQWE4MnR4Ni1zSXhObE5KSjgzbUMzUjUxWXQxZG9HamxyVUt5Qzh5blBrLURwdUp3c1c3b0tQUVhiUnVKYzZ6a2I5R0VGU01SSnhnUHA0NmFHc2M4VU02TjQtOHNfd3V0eWswMExnZ3RMeVNCVmlVb0VfazVTVG81RUpKZnNGRWNJUmYzNnJyTGRJSEpvUkdRUy0yXzBUVQ?oc=5" target="_blank">DeLLphi-301 Analysis: Tarlatamab Is Active in SCLC, Regardless of Baseline Brain Metastases</a>  <font color="#6f6f6f">DocWireNews</font>

Read Full StoryMore like this
Unexpected Acute Pancreatitis After Tarlatamab in Small Cell Lung Cancer: A Case Report
Cureusworld

Unexpected Acute Pancreatitis After Tarlatamab in Small Cell Lung Cancer: A Case Report

<a href="https://news.google.com/rss/articles/CBMiwwFBVV95cUxQTlpld2EyZTlvcDAycDVGNkdJeXBKcGdhZGZSWWctbU84R3k5R2xuQlVHekktUDJOYTg0RnZxbVd6cEJWVUJLRWxlSE5EazdmbG56R09MVHk5WlRESzFieVA5Y3RzSUYzaEFuazJ6S0E3N2U2cGhZTURiaUJvOUdBVWVFYzIwS3pndkppMVozdDlsNDVldDJsUXhrMUFYWG9wY1hwbVJBay1CV2cxR29rSmI0Mjd4dUNGS2lQNnp0MEJKR2s?oc=5" target="_blank">Unexpected Acute Pancreatitis After Tarlatamab in Small Cell Lung Cancer: A Case Report</a>  <font color="#6f6f6f">Cureus</font>

Read Full StoryMore like this
Tarlatamab Shows QOL, Symptom Benefits in Previously Treated SCLC
CancerNetworkgeneral

Tarlatamab Shows QOL, Symptom Benefits in Previously Treated SCLC

<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxQSFV4NjNQdkRsVE05V0VBZ3hVbWcxSzhHeHI5ZVdpS1VuRVpoR2FUaUhzeTBDSEhoejc5SWZ3aVljT1AzcDE3dUd6M1Jtc1NpNUdoSTU2bDNobEVwTkhiZEptRmVtalo3UHN6N3JiTFBPeVV3UkpOOFVaUUlYYXFEWGVQQXJlSktSbUp6MDVVZDhDQ0w3ZzF5UnYxTXV3V3cw?oc=5" target="_blank">Tarlatamab Shows QOL, Symptom Benefits in Previously Treated SCLC</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryMore like this
Tarlatamab Sustains Responses, Shows Long-Term Tolerability in Heavily Pretreated SCLC
OncLivetech

Tarlatamab Sustains Responses, Shows Long-Term Tolerability in Heavily Pretreated SCLC

<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxPWFNSNzZFazRkVXFKSjV0RXRybWI4RlJTU0RGUjVQWUF3bXI5UG5pTV85d2o0cDktRHp0LVNpUjZFbHZtR2hQcWpPWk5VOUNsa2M1Z1ltd1NiU0VTbTVCd1NHVWlJNmFGNk01U0hZeUJHQnR1MFgxWW1KN3dta0VWT29PeVJka2QzeElNUmJWQllyQ21TRXg2OVZGXzZMWndPbXRpcjZlRjZlMVlvdU50c3FwWVk?oc=5" target="_blank">Tarlatamab Sustains Responses, Shows Long-Term Tolerability in Heavily Pretreated SCLC</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
Tarlatamab Remains Safe and Effective in Extensive-Stage SCLC
CancerNetworktech

Tarlatamab Remains Safe and Effective in Extensive-Stage SCLC

<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxQNG5Ic0lVZHY3UWVnVHV3WlVkUllsTXl1ZzRnaDRIalpFQUFmNFI1OFpjMjlMR2t5eFZ3Sko3MHRrQm1xX0Q2cWRSdEVMMGZJeHVOMzdRVmFKaWREd2dWanpSenBHRmN3blFMVXlSbkJ4ekI4NDctcXZtVF9acm82XzhqTU9Ra1RsNUpBUVV5eHF1SDJwZTYxY2NicDQ?oc=5" target="_blank">Tarlatamab Remains Safe and Effective in Extensive-Stage SCLC</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryMore like this
Exploring T-Cell Engager Use in Chemotherapy-Resistant ES-SCLC
CancerNetworkgeneral

Exploring T-Cell Engager Use in Chemotherapy-Resistant ES-SCLC

<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxQWEUxazB5eDlLZHRwT2RYdlE1OGU4ZDFxZ0xRZnlhX0pnSmVNbE5zbHkzUWRWdDA5cGFzWXRWWlBFc0hqR1o0WXFaUTdQU3BwMW1mY0UwVThmT2pNOFFtWWFuTnBxTWxuMlAyVTd4VUJNT09xbjZrTjdUaXJvUzlYYXFHS2FiaTJBbzJvMkRMOXU3TVpBTE8zMWFOb0NsUQ?oc=5" target="_blank">Exploring T-Cell Engager Use in Chemotherapy-Resistant ES-SCLC</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryMore like this
Tarlatamab Safety Varies Between Clinical and Real-World SCLC Trials
The American Journal of Managed Careworld

Tarlatamab Safety Varies Between Clinical and Real-World SCLC Trials

<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxPQkZPeDJvNWY4V1QwM2xXYV82N0xpTjBueDd5V09tbHcwWXQwdUs1WFE3UGtMRTN4dkNad2dyUTdFLVJPTFdxSmNVR0toUGIwVDZoQ19kb2c0OHQ5UFBLV0FRbmdSdmpHbEpzc0RfSzBybFNfR2sxd0lsN0ZZWWtQS2FEZU9PeFk2QjhETktPWDJBY09lMm1LZnRB?oc=5" target="_blank">Tarlatamab Safety Varies Between Clinical and Real-World SCLC Trials</a>  <font color="#6f6f6f">The American Journal of Managed Care</font>

Read Full StoryMore like this
Tarlatamab Showed Shows Promise in Small-Cell Lung Cancer
Cure Todayworld

Tarlatamab Showed Shows Promise in Small-Cell Lung Cancer

<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxPUGpNcFEwekQ4eFQ2TTgzRGR3WDlLdkZoRjFRdXdSRTVFdEtGMThuYlQ0ZkdZbmNmTHp3bHVRUDd5LUU3a0RRNjE3c0RIeGxPQWg3RENyYVZFVEVLMFluVmVYdXV1Mk4tbm5sVkNGN094MHZqZFl1OXdMbmlhX3ppQVR4R2Izakx4UnNOLXJ3OWFxdw?oc=5" target="_blank">Tarlatamab Showed Shows Promise in Small-Cell Lung Cancer</a>  <font color="#6f6f6f">Cure Today</font>

Read Full StoryMore like this
"Tarlatamab Demonstrates S" — Live Google News Trends & Headlines